secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001689375-25-000041
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics reports Q2 net loss of $43.1M; cash runway into Q2 2027; advances DMD trials
--------------------------------------------------------------------------------

- Net loss of $43.1M in Q2 2025 vs net income of $55.0M in Q2 2024; collaboration revenue fell from $94.7M to $2.0M.
- Cash, cash equivalents and marketable securities $354M as of June 30, 2025; expected runway into Q2 2027.
- First patient dosed in ELEVATE-44-201 for DMD exon 44; data from first cohort expected H1 2026.
- Initiated ELEVATE-45-201 for exon 45; first patient dosing on track Q3 2025; cohort 1 data mid-2026.
- Expanded leadership: Navid Khan as SVP Medical Affairs, Kiran Patki as SVP Clinical Development; Maha Radhakrishnan joined Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000041/0001689375-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000041/trda-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001689375-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer